Clinical Trials
49 trialsNCT02319837 2026-05-07
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
Phase 3 Active not recruiting
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT05605964 2025-08-17
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT03035032 2024-11-26
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Astellas Pharma Inc
Phase 4 Completed
NCT03990194 2024-10-31
LEPTO
RECORDATI GROUP
Withdrawn
NCT06490328 2024-07-08
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Dongkook Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04914195 2023-08-01
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
Bharat Serums and Vaccines Limited
Phase 3 Completed
NCT01326312 2023-06-22
GTx758
GTx
Phase 2 Terminated
NCT02663908 2022-06-29
PRONOUNCE
Ferring Pharmaceuticals
Phase 3 Terminated
NCT05304169 2022-03-31
PRIZE
Zodiac Produtos Farmaceuticos S.A.
Phase 4 Completed
NCT03085095 2022-01-18
HERO
Myovant Sciences GmbH
Phase 3 Completed
NCT04783636 2021-03-17
To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers
Peptron, Inc.
Phase 1 Unknown
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT02085252 2019-06-28
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Phase 3 Completed
NCT03209492 2019-04-11
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
Takeda
Completed
NCT01547299 2018-10-23
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
Phase 2 Completed
NCT03662958 2018-09-10
Comparison of a Novel Leuprolide With Market Leuprolide
Lee's Pharmaceutical Limited
Phase NA Unknown
NCT02083185 2018-05-09
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
Takeda
Phase 2 Completed
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT02107391 2017-05-24
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
Sotio Biotech Inc.
Phase 2 Completed
NCT02212197 2017-04-25
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Camurus AB
Phase 2 Completed
NCT02167893 2017-03-29
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"
Takeda
Completed
NCT01933022 2017-03-09
EFFECT
Astellas Pharma Inc
Phase 4 Terminated
NCT01415960 2017-03-03
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
GP-Pharm
Phase 3 Completed
NCT03029533 2017-01-24
Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer
Daewoong Pharmaceutical Co. LTD.
Phase 1 Unknown
NCT00928434 2016-12-13
A Study of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT02128334 2016-08-16
An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation
Astellas Pharma Inc
Completed
NCT02749825 2016-04-25
Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
Pharmatech
Phase 4 Terminated
NCT00817739 2015-07-29
Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c
Takeda
Phase 2 Completed
NCT00378690 2014-06-04
ICELAND
Astellas Pharma Inc
Phase 3 Completed
NCT01088529 2014-05-15
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT01793077 2014-01-13
TREMODI
Astellas Pharma Inc
Completed
NCT00514917 2013-11-04
Rising PSA
Sanofi
Phase 3 Terminated
NCT01161563 2013-09-06
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
Phase 4 Completed
NCT00924469 2013-04-17
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT00451958 2013-03-21
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Ferring Pharmaceuticals
Phase 3 Completed
NCT00295750 2012-12-19
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT01081873 2012-10-31
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer
Abbott
Completed
NCT00075192 2012-06-06
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
AstraZeneca
Phase 1/2 Completed
NCT01132404 2012-01-31
Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
Millennium Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT00283062 2012-01-26
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
Sanofi
Phase 3 Completed
NCT01078545 2012-01-16
LEMON
Abbott
Completed
NCT00626431 2011-07-19
A Study of Leuprolide to Treat Prostate Cancer
Abbott
Phase 3 Completed
NCT00630799 2010-09-09
Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
GP-Pharm
Phase 3 Terminated
NCT00598312 2010-09-08
Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
Oakwood Laboratories, LLC
Phase 3 Completed
NCT00056654 2008-09-17
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
Abbott
Phase NA Completed
NCT00076531 2008-01-28
Clinical Trial for Prostate Cancer
Oakwood Laboratories, LLC
Phase 3 Completed
NCT00128531 2007-11-14
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
GP-Pharm
Phase 3 Completed